Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
Axsome Therapeutics presented new clinical data on its sleep disorder medicines AXS-12 and solriamfetol at SLEEP 2026, highlighting positive cognitive, functional, and quality-of-life outcomes in narcolepsy and obstructive sleep apnea patients. These presentations reinforce Axsome's leadership in central nervous system disorder treatments and its i…